US and UK researchers have identified a unique subset of helper T-cells called ‘peripheral helper’ T-cells in the synoviums that may be linked to the pathogenesis of rheumatoid arthritis.
All News
Up to 30% of patients with rheumatoid arthritis (RA) will eventually undergo joint reconstructive surgery, yet we have limited data to guide the perioperative management of DMARDs and biologics.
Dr. Jack Cush reviews this week's highlights from RheumNow.
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Dr. Cush reviews highlights from the past week on RheumNow.com.
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Dr. Jack Cush reviews highlights from the past week on RheumNow.
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Colitis onset or worsening inflammatory bowel disease has been reported with either of the new IL-17 inhibitors, ixekizumab (IXE) and secukinumab (SEC). Large database studies show these to be rare.
